OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

Phase 4 Completed 75 enrolled Center for Ophthalmic and Vision Research, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a single center, prospective, randomized, controlled, double-masked, two-arm investigator-initiated study to investigate the efficacy of OC-01 (varenicline) nasal spray on the signs and symptoms of dry eye disease in daily soft contact lens wearers.

Timeline

Start: 2021-12-03
Primary completion: 2022-07-25
Completion: 2022-07-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OC-01	Small molecule	0.6 mg/ml	Intranasal

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

Summary

Timeline

Drugs

Indications